CV

CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.

Wall Street analysts forecast CV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CV is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CapsoVision Inc revenue for the last quarter amounts to 3.54M USD, increased 19.29 % YoY.

CapsoVision Inc. EPS for the last quarter amounts to -0.17 USD, increased 30.77 % YoY.

CapsoVision Inc (CV) has 90 emplpoyees as of January 07 2026.

Today CV has the market capitalization of 372.40M USD.